Adam Koppel - Jun 7, 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: Director, 10%+ Owner
Signature: /s/ Adam Koppel
Stock symbol: CERE
Transactions as of: Jun 7, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/9/2023, 05:07 PM
Previous filing: Jun 8, 2023
Next filing: Jun 22, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Award		+3.28K			3.28K	Jun 7, 2023	Direct	F1
transaction	CERE	Common Stock	Other	$0	-433K	-0.71%	$0.00	60.2M	Jun 7, 2023	See footnotes	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Award	$0	+13.8K		$0.00	13.8K	Jun 7, 2023	Common Stock	13.8K	$32.60	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date.
F2	100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date.
F3	On June 7, 2023, BC Perception Holdings, LP ("BC Perception") distributed an aggregate of 432,627 shares of the Issuer's common stock (the "Distributed Shares") to certain of its limited partners in a pro-rata in-kind distribution to such limited partners in connection with a redemption of their partnership interests. Dr. Koppel did not have a pecuniary interest in any of the Distributed Shares.
F4	Adam Koppel is a Partner of Bain Capital Life Sciences Investors, LLC, which is the ultimate general partner of Bain Capital Life Sciences Fund, L.P. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.